The role of the size in thyroid cancer risk stratification

Abstract Only a minority of cases of differentiated thyroid carcinoma (DTC) have a poor clinical outcome. Clinical outcomes and molecular aspects were assessed in: 144 DTC ≤ 40 mm without distant metastases (group 1); 50 DTC > 40 mm without distant metastases (group 2); and 46 DTC with distant me...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Federica Vianello, Simona Censi, Sara Watutantrige-Fernando, Susi Barollo, Yi Hang Zhu, Nora Albiger, Loris Bertazza, Jacopo Manso, Sofia Carducci, Clara Benna, Maurizio Iacobone, Francesca Galuppini, Gianmaria Pennelli, Caterina Mian
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d58f9886347847eeb2f9b3ca3f8c2ef7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d58f9886347847eeb2f9b3ca3f8c2ef7
record_format	dspace
spelling	oai:doaj.org-article:d58f9886347847eeb2f9b3ca3f8c2ef72021-12-02T14:23:23ZThe role of the size in thyroid cancer risk stratification10.1038/s41598-021-86611-62045-2322https://doaj.org/article/d58f9886347847eeb2f9b3ca3f8c2ef72021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-86611-6https://doaj.org/toc/2045-2322Abstract Only a minority of cases of differentiated thyroid carcinoma (DTC) have a poor clinical outcome. Clinical outcomes and molecular aspects were assessed in: 144 DTC ≤ 40 mm without distant metastases (group 1); 50 DTC > 40 mm without distant metastases (group 2); and 46 DTC with distant metastases (group 3). Group 3 had a worse outcome than the other two groups: during the follow-up, patients more frequently had persistent disease, died, or underwent further treatment. The outcomes did not differ between groups 1 and 2. Group 3 had a higher prevalence of TERT promoter mutations than group 2 (32.6% vs 14%). Group 1 had a higher frequency of BRAF mutations than groups 2 or 3 (61.1% vs 16.0% and 26.1%, respectively), while RAS mutations were more common in group 2 than in groups 1 and 3 (16.0% vs 2.1% and 6.5%, respectively). Groups 1 and 2 shared the same outcome, but were genetically distinct. Only lymph node involvement, distant metastases, older age and (among the molecular markers) TERT promoter mutations were independent predictors of a worse outcome. Metastatic DTC had the worst outcome, while the outcome was identical for large and small non-metastatic DTC, although they showed different molecular patterns. TERT promoter mutations emerged as an independent factor pointing to a poor prognosis.Federica VianelloSimona CensiSara Watutantrige-FernandoSusi BarolloYi Hang ZhuNora AlbigerLoris BertazzaJacopo MansoSofia CarducciClara BennaMaurizio IacoboneFrancesca GaluppiniGianmaria PennelliCaterina MianNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Federica Vianello Simona Censi Sara Watutantrige-Fernando Susi Barollo Yi Hang Zhu Nora Albiger Loris Bertazza Jacopo Manso Sofia Carducci Clara Benna Maurizio Iacobone Francesca Galuppini Gianmaria Pennelli Caterina Mian The role of the size in thyroid cancer risk stratification
description	Abstract Only a minority of cases of differentiated thyroid carcinoma (DTC) have a poor clinical outcome. Clinical outcomes and molecular aspects were assessed in: 144 DTC ≤ 40 mm without distant metastases (group 1); 50 DTC > 40 mm without distant metastases (group 2); and 46 DTC with distant metastases (group 3). Group 3 had a worse outcome than the other two groups: during the follow-up, patients more frequently had persistent disease, died, or underwent further treatment. The outcomes did not differ between groups 1 and 2. Group 3 had a higher prevalence of TERT promoter mutations than group 2 (32.6% vs 14%). Group 1 had a higher frequency of BRAF mutations than groups 2 or 3 (61.1% vs 16.0% and 26.1%, respectively), while RAS mutations were more common in group 2 than in groups 1 and 3 (16.0% vs 2.1% and 6.5%, respectively). Groups 1 and 2 shared the same outcome, but were genetically distinct. Only lymph node involvement, distant metastases, older age and (among the molecular markers) TERT promoter mutations were independent predictors of a worse outcome. Metastatic DTC had the worst outcome, while the outcome was identical for large and small non-metastatic DTC, although they showed different molecular patterns. TERT promoter mutations emerged as an independent factor pointing to a poor prognosis.
format	article
author	Federica Vianello Simona Censi Sara Watutantrige-Fernando Susi Barollo Yi Hang Zhu Nora Albiger Loris Bertazza Jacopo Manso Sofia Carducci Clara Benna Maurizio Iacobone Francesca Galuppini Gianmaria Pennelli Caterina Mian
author_facet	Federica Vianello Simona Censi Sara Watutantrige-Fernando Susi Barollo Yi Hang Zhu Nora Albiger Loris Bertazza Jacopo Manso Sofia Carducci Clara Benna Maurizio Iacobone Francesca Galuppini Gianmaria Pennelli Caterina Mian
author_sort	Federica Vianello
title	The role of the size in thyroid cancer risk stratification
title_short	The role of the size in thyroid cancer risk stratification
title_full	The role of the size in thyroid cancer risk stratification
title_fullStr	The role of the size in thyroid cancer risk stratification
title_full_unstemmed	The role of the size in thyroid cancer risk stratification
title_sort	role of the size in thyroid cancer risk stratification
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/d58f9886347847eeb2f9b3ca3f8c2ef7
work_keys_str_mv	AT federicavianello theroleofthesizeinthyroidcancerriskstratification AT simonacensi theroleofthesizeinthyroidcancerriskstratification AT sarawatutantrigefernando theroleofthesizeinthyroidcancerriskstratification AT susibarollo theroleofthesizeinthyroidcancerriskstratification AT yihangzhu theroleofthesizeinthyroidcancerriskstratification AT noraalbiger theroleofthesizeinthyroidcancerriskstratification AT lorisbertazza theroleofthesizeinthyroidcancerriskstratification AT jacopomanso theroleofthesizeinthyroidcancerriskstratification AT sofiacarducci theroleofthesizeinthyroidcancerriskstratification AT clarabenna theroleofthesizeinthyroidcancerriskstratification AT maurizioiacobone theroleofthesizeinthyroidcancerriskstratification AT francescagaluppini theroleofthesizeinthyroidcancerriskstratification AT gianmariapennelli theroleofthesizeinthyroidcancerriskstratification AT caterinamian theroleofthesizeinthyroidcancerriskstratification AT federicavianello roleofthesizeinthyroidcancerriskstratification AT simonacensi roleofthesizeinthyroidcancerriskstratification AT sarawatutantrigefernando roleofthesizeinthyroidcancerriskstratification AT susibarollo roleofthesizeinthyroidcancerriskstratification AT yihangzhu roleofthesizeinthyroidcancerriskstratification AT noraalbiger roleofthesizeinthyroidcancerriskstratification AT lorisbertazza roleofthesizeinthyroidcancerriskstratification AT jacopomanso roleofthesizeinthyroidcancerriskstratification AT sofiacarducci roleofthesizeinthyroidcancerriskstratification AT clarabenna roleofthesizeinthyroidcancerriskstratification AT maurizioiacobone roleofthesizeinthyroidcancerriskstratification AT francescagaluppini roleofthesizeinthyroidcancerriskstratification AT gianmariapennelli roleofthesizeinthyroidcancerriskstratification AT caterinamian roleofthesizeinthyroidcancerriskstratification
_version_	1718391455063474176

The role of the size in thyroid cancer risk stratification

Ejemplares similares